Vera Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period
Vera Therapeutics, Inc. (VERA) reported Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period of 220.04 thousand shares for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod · last filed 2026-05-07
- Vera Therapeutics, Inc. share-based compensation arrangement by share-based payment award, shares issued in period for the quarter ending 2026-03-31 was 220.04K shares, a 96.15% increase year-over-year.
- Vera Therapeutics, Inc. share-based compensation arrangement by share-based payment award, shares issued in period for the quarter ending 2025-12-31 was 0.00 shares.
- Vera Therapeutics, Inc. share-based compensation arrangement by share-based payment award, shares issued in period for the quarter ending 2025-09-30 was 37.91K shares, a 388.32% increase year-over-year.
- Vera Therapeutics, Inc. share-based compensation arrangement by share-based payment award, shares issued in period for the quarter ending 2025-06-30 was 0.00 shares.
- Vera Therapeutics, Inc. share-based compensation arrangement by share-based payment award, shares issued in period for fiscal 2025 was 150.09K shares, a 69.11% increase from fiscal 2024.
- Vera Therapeutics, Inc. share-based compensation arrangement by share-based payment award, shares issued in period for fiscal 2024 was 88.75K shares, a 48.39% increase from fiscal 2023.
- Vera Therapeutics, Inc. share-based compensation arrangement by share-based payment award, shares issued in period for fiscal 2023 was 59.81K shares, a 290.19% increase from fiscal 2022.
- Vera Therapeutics, Inc. share-based compensation arrangement by share-based payment award, shares issued in period for fiscal 2022 was 15.33K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period 12 month |
|---|---|---|---|---|
| 2026-03-31 | 220.04K shares 10-Q · filed 2026-05-07 | 220.04K shares derived: sum of 2 quarters · filed 2026-05-07 | 257.95K shares derived: sum of 3 quarters · filed 2026-05-07 | 257.95K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 37.91K shares derived: sum of 2 quarters · filed 2026-02-26 | 37.91K shares derived: sum of 3 quarters · filed 2026-02-26 | 150.09K shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 37.91K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 37.91K shares derived: sum of 2 quarters · filed 2025-11-05 | 150.09K shares 10-Q · filed 2025-11-05 | 150.09K shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 112.18K shares 10-Q · filed 2025-08-05 | 112.18K shares derived: sum of 3 quarters · filed 2025-08-05 | 119.94K shares derived: sum of 4 quarters · filed 2025-08-05 |
| 2025-03-31 | 112.18K shares 10-Q · filed 2025-05-07 | 112.18K shares derived: sum of 2 quarters · filed 2025-05-07 | 119.94K shares derived: sum of 3 quarters · filed 2025-05-07 | 119.94K shares derived: sum of 4 quarters · filed 2025-05-07 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | 7.76K shares derived: sum of 2 quarters · filed 2025-02-28 | 7.76K shares derived: sum of 3 quarters · filed 2025-02-28 | 88.75K shares 10-K · filed 2025-02-28 |
| 2024-09-30 | 7.76K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 7.76K shares derived: sum of 2 quarters · filed 2024-11-07 | 88.75K shares 10-Q · filed 2024-11-07 | 88.75K shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 80.99K shares 10-Q · filed 2024-08-08 | 80.99K shares derived: sum of 3 quarters · filed 2024-08-08 | 97.54K shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 80.99K shares 10-Q · filed 2024-05-10 | 80.99K shares derived: sum of 2 quarters · filed 2024-05-10 | 97.54K shares derived: sum of 3 quarters · filed 2024-05-10 | 97.54K shares derived: sum of 4 quarters · filed 2024-05-10 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | 16.55K shares derived: sum of 2 quarters · filed 2024-03-27 | 16.55K shares derived: sum of 3 quarters · filed 2024-03-27 | 59.81K shares 10-K · filed 2024-03-27 |
| 2023-09-30 | 16.55K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 16.55K shares derived: sum of 2 quarters · filed 2023-11-09 | 59.81K shares 10-Q · filed 2023-11-09 | 59.81K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 43.25K shares 10-Q · filed 2023-08-10 | 43.25K shares derived: sum of 3 quarters · filed 2023-08-10 | |
| 2023-03-31 | 43.25K shares 10-Q · filed 2023-05-11 | 43.25K shares derived: sum of 2 quarters · filed 2023-05-11 | ||
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | 15.33K shares 10-K · filed 2023-03-28 | ||
| 2022-09-30 | 15.33K shares 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |